| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa1c04d489d41439c95ff9d80fc8c110 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6081
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-577
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6037 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2016-11-02^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-10-26^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2e1c33cb92afd38a7d0c39f95203479
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b5e7ce78c232f3a4218eb8f6a99ab9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f46846ef39f3b7eabe8e04f5273cb417
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b28e3469325eefdc486bd8d0bb062ca9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cf918becd7cade3c9cb3e4c54070be26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78e54ea05b4ef0f58d6cf81dea1cb090 |
| publicationDate |
2020-10-26^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2734924-C2 |
| titleOfInvention |
Method for autoantigen vaccination in a human patient |
| abstract |
FIELD: medicine; pharmaceuticals.SUBSTANCE: disclosed is a method for autoantigen vaccination in a human patient, where a dose with an effective amount of autoantigen is used in a patient to induce a primary immune response, characterized by that the patient is subjected to a booster application of the above autoantigen, where the amount of autoantigen in a dose for booster application is higher than the amount of autoantigen in a dose used for the purpose of the primary immune response.EFFECT: what is presented is a method for autoantigen vaccination in a human patient.21 cl, 9 dwg |
| priorityDate |
2015-11-03^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |